Latest News

(UroToday.com) There has been a rapid evolution in treatment options for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) since the spring of 2018. Up until the presentation of SPARTAN and PROSPER trials, reporting on the use of apalutamide and enzalutamide in nmCRPC, at GU ASCO in February 2018, there were no specifically approved treatment options […]

(UroToday.com) In 2016, Colin Pritchard and colleagues reported that mutations in DNA-damage repair genes, particularly homologous recombination repair genes, were relatively common among patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This opened the potential for targeted therapy using poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors which lead to an accumulation of DNA single-stranded breaks which have […]

(UroToday.com) Androgen receptor-targeted agents represent one of the main treatment options for men with metastatic castrate-resistant prostate cancer (mCRPC). The addition of stereotactic radiation therapy to ablate metastatic foci may improve clinical outcomes in oligometastatic setting. The ARTO trial (NCT03449719) is a randomized phase II trial testing the benefit of upfront stereotactic body radiation therapy on […]

(UroToday.com) Enzalutamide plus ADT is approved in the US and Europe to treat castration-resistant prostate cancer and was also recently approved for men with metastatic hormone-sensitive prostate cancer (mHSPC) in the US. In ARCHES, enzalutamide plus ADT reduced the risk of the primary endpoint of radiographic progression-free survival events (by 61%), and improved key secondary endpoints […]

(UroToday.com) Among men with metastatic castration-resistant prostate cancer (mCRPC), there is a subset who develop aggressive variant or neuroendocrine/small-cell-like (NE/SC) tumors.  These men display particularly poor outcomes. Although a field of active investigation of underlying mechanisms of development, effective therapies remain a clear unmet clinical need.  The current standard of care is typically platinum- or taxane-based chemotherapies.  The investigators […]

(UroToday.com) It is increasingly well-known that African American (AA) men as a group experience higher incidence of prostate cancer and worse prostate cancer-specific outcomes. The reasons for this are the point of ongoing investigations, with contributors to disparity from biological and non-biological factors. Within the realm of differential biology lie the data that AA men have […]

Background Lutetium-177 [¹⁷⁷Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA), with activity and safety in patients with metastatic castrationresistant prostate cancer. We aimed to compare [¹⁷⁷Lu]Lu-PSMA-617 with cabazitaxel in patients with metastatic castration-resistant prostate cancer. Methods We did this multicentre, unblinded, randomised phase 2 trial at […]

San Francisco, CA (UroToday.com) — The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) reports the results of its “TheraP” (ANZUP 1603) clinical trial at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Virtual Symposium.

(UroToday.com) At the 2021 American Society of Clinical Oncology Genitourinary Cancers annual meeting (ASCO GU), Dr. Daniel George and colleagues presented a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of the oral GnRH receptor antagonist relugolix versus leuprolide in men with advanced prostate cancer. In the phase 3 HERO study,1 […]

(UroToday.com) It remains that African American (AA) men experience higher rates of incidence of prostate cancer and prostate cancer-specific mortality than do their non-AA counterparts. Multifaceted efforts are underway at several centers to isolate and address the biological and non-biological contributors to these fundamental health disparities. Among a gap between AA and non-AA prostate cancer patients […]